Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | PAM | P19021 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172825 | 1.00 | IDO1 (0.58) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL4863423 | 0.80 | IDO1 (0.58) | IDO1PAMMAOBHTR2ANPC1 | |
| SCHEMBL9777486 | 0.80 | IDO1 (0.58) | IDO1PAMMAOBHTR2ANPC1 | |
| SCHEMBL2064116 | 0.80 | SIGMAR1 (0.48) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL97891 | 0.79 | PAM (0.58) | IDO1PAMMAOBHTR2A | |
| SCHEMBL97892 | 0.79 | PAM (0.58) | IDO1PAMMAOBHTR2A | |
| SCHEMBL7385940 | 0.79 | PAM (0.58) | IDO1PAMMAOBHTR2A | |
| SCHEMBL15302084 | 0.78 | IDO1 (0.47) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL73341 | 0.78 | IDO1 (0.47) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL5411876 | 0.78 | HTR2A (0.48) | IDO1PAMMAOBHTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602952-B1 | Hydrogels, which are cross-linked polymers that swell in water, have potential as drug delivery vehicles | SHEARWATER CORPORATION | 2003-08-05 | — | — | US | claimed |
| JP-2003503367-A | — | — | 2003-01-28 | — | — | JP | claimed |
| EP-1223986-A2 | HYDROGELS DERIVED FROM CHITOSAN AND POLY(ETHYLENE GLYCOL) | Shearwater Corporation (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2001000246-A2 | HYDROGELS DERIVED FROM CHITOSAN AND POLY(ETHYLENE GLYCOL) | SHEARWATER CORPORATION (US) | 2001-01-04 | — | — | WO | claimed |
| EP-0881205-A1 | Method for production of allyloxystyrene compounds | LOCTITE CORPORATION (US) | 1998-12-02 | — | — | EP | claimed |
| US-5633411-A | Method for production of allyloxystyrene compounds | LOCTITE CORPORATION (US) | 1997-05-27 | — | — | US | claimed |
| US-5250393-A | Containing diazo resin and alkali metal or ammonium silicate | FUJI PHOTO FILM CO., LTD. (JP) | 1993-10-05 | — | — | US | claimed |
| CN-118702853-A | Method for terminating anion polymerization and removing initiator | 青岛玄道科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-11685702-B2 | Method for producing arene compounds and arene compounds produced by the same | JSI SILICONE CO. (KR) | 2023-06-27 | — | — | US | disclosed |
| US-11565995-B2 | Methods of forming imines, imine-related and imine-derived compounds using green solvents | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210323911-A1 | METHODS OF FORMING IMINES, IMINE-RELATED AND IMINE-DERIVED COMPOUNDS USING GREEN SOLVENTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-10-21 | — | — | US | disclosed |
| US-20210188739-A1 | METHOD FOR PRODUCING ARENE COMPOUNDS AND ARENE COMPOUNDS PRODUCED BY THE SAME | JSI SILICONE CO. (KR) | 2021-06-24 | — | — | US | disclosed |
| EP-3353167-B1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-06-24 | — | — | EP | disclosed |
| WO-1999010338-A2 | BENZYLIDENE- AND CINNAMYLIDENE-ANABASEINES AS NEURONAL NICOTINIC ALPHA-7 RECEPTOR AGONISTS | UNIVERSITY OF FLORIDA (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0881205-A1 | Method for production of allyloxystyrene compounds | LOCTITE CORPORATION (US) | 1998-12-02 | — | — | EP | disclosed |
| US-5633411-A | Method for production of allyloxystyrene compounds | LOCTITE CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| US-4025695-A | LAMINATION | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
| US-3985832-A | BY REACTING CHLORINATED RUBBER WITH A BROMINE OR IODINE COMPOUND | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3976640-A | CYANINE | POLAROID CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
| US-3968094-A | Photodegradable plastics containing haloolefins | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF AGRICULTURE (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188739-A1 | METHOD FOR PRODUCING ARENE COMPOUNDS AND ARENE COMPOUNDS PRODUCED BY THE SAME | PFAS, FRK, AGPAT2 | IDO1 2819/4885PAM 835/4885MAOB 781/4885 |
| US-11685702-B2 | Method for producing arene compounds and arene compounds produced by the same | PFAS, FRK, AGPAT2 | IDO1 2819/4885PAM 835/4885MAOB 781/4885 |
| US-20210323911-A1 | METHODS OF FORMING IMINES, IMINE-RELATED AND IMINE-DERIVED COMPOUNDS USING GREEN SOLVENTS | IK, LDHB, IDH3B | IDO1 30/4885PAM 1421/4885MAOB 631/4885 |
| US-11565995-B2 | Methods of forming imines, imine-related and imine-derived compounds using green solvents | IK, LDHB, IDH3B | IDO1 30/4885PAM 1421/4885MAOB 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.